BioSpace News Archive

Aeglea BioTherapeutics, Inc. today announced its participation in two investor conferences as follows: Conference: 40th Annual J.P. Morgan Health Care Conference.

Cogent Biosciences, Inc. today provided 2021 year-end updates and corporate guidance for 2022.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia , Ph.D., chief executive officer, will present a company overview at the virtual 40th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. ET on Wednesday, January 12, 2022.

4D pharma plc announced that Duncan Peyton, Chief Executive Officer of 4D pharma, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will present at the H.C. Wainwright BioConnect Conference.

Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing.

Asher Biotherapeutics today announced that Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:30 p.m. ET (12:30 p.m. PT).

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming Biotech Showcase at J.P. Morgan Healthcare Conference, to be held in a virtual format from January 10-12 and 17-19.

Partnership aims to drive innovation and clinical development of novel therapeutics for cancer treatment.

Moderna today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company’s Epstein-Barr Virus (EBV) vaccine candidate.

InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa patients with active draining tunnels.